{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:03:47Z","timestamp":1791389027928,"version":"4.3.3"},"update-to":[{"DOI":"10.1002\/14651858.cd014570","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000}}],"reference-count":134,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014570.pub2","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T11:22:39Z","timestamp":1685532159000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["PEG-asparaginase treatment\u00a0regimens for acute lymphoblastic leukaemia in children: a network meta-analysis"],"prefix":"10.1002","volume":"2023","author":[{"given":"Line Stensig","family":"Lynggaard","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Medicine; Aarhus University Hospital; Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie U","family":"Rank","sequence":"additional","affiliation":[{"name":"Department of Haematology; Rigshospitalet, University Hospital of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodil","family":"Als-Nielsen","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\/Oncology (5054); The Child and Youth Clinic; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie G","family":"Hoejfeldt","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Medicine; Aarhus University Hospital; Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Heyman","sequence":"additional","affiliation":[{"name":"Childhood Cancer Research Unit, Department of Women\u2019s and Children\u2019s Health; Karolinska Institutet and Karolinska University Hospital; Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine; Rigshospitalet, University Hospital of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte K","family":"Albertsen","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Medicine; Aarhus University Hospital; Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"10.1002\/14651858.CD014570.pub2-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Albertsen B K Abrahamsson J Lund B Vettenranta K Jonsson O G Frandsen T L Wolthers B O Grell K Heyman M Schmiegelow K Intermittent vs continuous asparaginase to reduce asparaginase-associated toxicities: a nopho all2008 randomized study Blood 2017","DOI":"10.2139\/ssrn.3234898"},{"issue":"19","key":"10.1002\/14651858.CD014570.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.18.01877","article-title":"Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study","volume":"37","author":"Albertsen B","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0003|cit3","unstructured":"Euctr F I NOPHO ALL2008 http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2008-003235-20-FI 2008;(): 2008"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0004|cit4","unstructured":"ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase https:\/\/clinicaltrials.gov\/show\/NCT00819351 2009;():2009 2009"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0005|cit5","unstructured":"Vogt H Davidson T Heyman M Malmros J Mogensen N Stenmarker M Harila-Saari A A cost analysis of childhood acute lymphoblastic leukemic randomised to treatment with peg-asparaginase administered at either 2-or 6-week intervals Pediatric Blood & Cancer 2018 S109-"},{"issue":"6","key":"10.1002\/14651858.CD014570.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.19.01086","article-title":"Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331","volume":"38","author":"Maloney K","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0007|cit7","unstructured":"Maloney K Devidas M Mattano L Friedmann A Rabin K Buckley P Excellent Event-Free (EFS) and Overall Survival (OS) for children with Down Syndrome (DS) with Standard Risk B-Acute Lymphoblastic Leukemia (SR B-ALL): results of Children's Oncology Group (COG) AALL0331 Pediatric Blood & Cancer 2018 S1-"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Mattano L A Devidas M Friedmann A M Raetz E A Loh M Buckley P Borowitz M J Carroll A J Gastier-Foster J Heerema N A Kadan-Lottick N Matloub Y Marshall D T Stork L C Wood B L Winick N J Hunger S Carroll W L Maloney K Outstanding outcome for children with standard risk-low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and no benefit to intensified peg-asparaginase (PEG-ASNase) therapy: Results of children's oncology group (COG) Study AALL0331 Blood. Conference: 56th Annual Meeting of the American Society of Hematology, ASH 2014","DOI":"10.1182\/blood.V124.21.793.793"},{"issue":"14","key":"10.1002\/14651858.CD014570.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1200\/JCO.20.02370","article-title":"Favorable trisomies and ETV6-RUNX1 predict cure in low-risk B-Cell acute lymphoblastic leukemia: Results from Children's Oncology Group trial AALL0331","volume":"39","author":"Mattano Leonard","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0010|cit10","unstructured":"Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma ClinicalTrials.gov 2010"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0011|cit11","unstructured":"SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma Clinicaltrials.gov. 2012"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Silverman L B Blonquist T M Hunt S K Kay-Green S Athale U H Clavell L A Cole P D Kelly K M Laverdiere C Leclerc J M Randomized study of pegasparagase (SS-PEG) and calaspargase pegol (SC-PEG) in pediatric patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma: results of DFCI ALL consortium protocol 11-001 Blood 2016","DOI":"10.1182\/blood.V128.22.175.175"},{"issue":"31","key":"10.1002\/14651858.CD014570.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.20.03692","article-title":"Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001","volume":"39","author":"Vrooman L","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Vrooman L M Blonquist T M Supko J G Hunt S K O'Brien J E Kay-Green S Athale U H Clavell L A Cole P D Harris M H Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia\/lymphoma: results of DFCI 11-001 Journal of clinical oncology 2019","DOI":"10.1200\/JCO.2019.37.15_suppl.10006"},{"issue":"34","key":"10.1002\/14651858.CD014570.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","article-title":"Pharmacokinetic and pharmacodynamic properties of Calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: Results from Children's Oncology Group study AALL07P4","volume":"32","author":"Angiolillo A","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1200\/jco.2012.30.15_suppl.9543","article-title":"Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG e. coli L-asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia(ALL): Results from Children's Oncology Group (COG) study AALL07P4","volume":"30 (15 suppleme","author":"Angiolillo A","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"35","key":"10.1002\/14651858.CD014570.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"3377-3391","DOI":"10.1200\/JCO.19.01692","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: st Jude total therapy study 16","volume":"37","author":"Jeha","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"25","key":"10.1002\/14651858.CD014570.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood.2020006214","article-title":"Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment","volume":"136","author":"Liu","year":"2020","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0019|cit19","unstructured":"Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia https:\/\/clinicaltrials.gov\/show\/NCT00549848 2007;():2007 2007"},{"issue":"15 (supplement)","key":"10.1002\/14651858.CD014570.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"10035","DOI":"10.1200\/jco.2015.33.15_suppl.10035","article-title":"Association of intravenous (IV) and intramuscular (IM) pegaspargase (PEG) administration with rate of adverse events (AE) in standard risk (SR) acute lymphoblastic leukemia (ALL) Children's Oncology Group (COG) trials","volume":"33","author":"Maloney K","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD014570.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.19.01086","article-title":"Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331","volume":"38","author":"Maloney K","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD014570.pub2-BIB0022|cit22","first-page":"337","article-title":"Efficacy and toxicity of pegylated asparaginase in the treatment of children and young adults with acute lymphoblastic leukaemia: Results of the United Kingdom Medical Research Council (MRC) trial UKALL 2003","volume":"112","author":"Vora","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Vora A J Mitchell C Goulden N Richards S UKALL 2003, a randomised trial investigating treatment reduction for children and young adults with minimal residual disease defined low risk acute lymphoblastic leukaemia Blood 2010","DOI":"10.1182\/blood.V116.21.496.496"},{"issue":"3","key":"10.1002\/14651858.CD014570.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0025|cit25","first-page":"46","article-title":"Post-remission MRD kinetics in children with acute lymphoblastic leukaemia receiving augmented BFM consolidation compared with other regimens: Update of results of the medical research council trial UKALL2003","volume":"145","author":"Cutting","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Patrick K Wade R Goulden N Mitchell C Rowntree C Improved outcome for children and young people with T-acute lymphoblastic leukaemia: Results of the UKALL 2003 trial Blood 2014","DOI":"10.1182\/blood.V124.21.3702.3702"},{"issue":"8","key":"10.1002\/14651858.CD014570.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8","article-title":"Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial","volume":"15","author":"Vora","year":"2014","journal-title":"The Lancet Oncology"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0028|cit28","unstructured":"A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents https:\/\/clinicaltrials.gov\/show\/NCT02716233 2016;():2016 2016"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0029|cit29","unstructured":"A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04954326 2021"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0030|cit30","unstructured":"Euctr N L Treatment with chemotherapy for children >1 and <19 years of age with acute lymphoblastic leukemia http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2012-000067-25-NL 2012;(): 2012"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0031|cit31","unstructured":"Protocol DCOG ALL-11 http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=NTR3379 2012;(): 2012"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0032|cit32","unstructured":"Bleckmann K Alten J Schrappe M Vieth S Moricke A Bodmer N Zapotocka E Barbaric D Zimmermann M Hypoglycemic events during treatment of pediatric acute lymphoblastic leukemia: Observations from trial AIEOP-BFM all 2009 Haematologica 2017 350 351"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0033|cit33","unstructured":"Euctr DE International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2007-004270-43-DE 2009;(): 2009"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0034|cit34","unstructured":"Euctr DE International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-001935-12-DE 2018;(): 2018"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0035|cit35","unstructured":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia https:\/\/clinicaltrials.gov\/show\/NCT01117441 2010;():2010 2010"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0036|cit36","doi-asserted-by":"crossref","unstructured":"Rizzari C Moericke A Conter V Valsecchi M G Zimmermann M Silvestri D Mann G Niggli F Dalla-Pozza L Stary J Elitzur S Cario G Locatelli F Boos J Zucchetti M Biondi A Schrappe M Incidence of hypersensitivity reactions (HSR) reactions (HSR) to peg-asparaginase (PEG-ASP) in 6136 patients treated in the AIEOP-BFM ALL 2009 study protocol Blood 2019","DOI":"10.1182\/blood-2019-123448"},{"issue":"4","key":"10.1002\/14651858.CD014570.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1046\/j.1365-2141.1997.d01-2089.x","article-title":"Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia","volume":"96","author":"Ahlke","year":"1997","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"Jco1801877","DOI":"10.1200\/JCO.18.01877","article-title":"Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: a NOPHO ALL2008 randomized study","volume":"37","author":"Albertsen","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD014570.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/asheducation.V2014.1.181.3882466","article-title":"Clinically defining and managing high-risk pediatric patients with acute lymphoblastic leukemia","volume":"2014","author":"Alexander","year":"2014","journal-title":"Hematology \/ the Education Program of the American Society of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD014570.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.leu.2401310","article-title":"Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study","volume":"13","author":"Amylon","year":"1999","journal-title":"Leukemia"},{"issue":"9","key":"10.1002\/14651858.CD014570.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","article-title":"Comparative pharmacokinetic studies of three asparaginase preparations","volume":"11","author":"Asselin","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD014570.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3109\/10428194.2014.1003056","article-title":"Asparaginase pharmacokinetics and implications of therapeutic drug monitoring","volume":"56","author":"Asselin","year":"2015","journal-title":"Leukemia & Lymphoma"},{"issue":"7454","key":"10.1002\/14651858.CD014570.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD014570.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD014570.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","article-title":"Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future","volume":"44","author":"Avramis","year":"2005","journal-title":"Clinical Pharmacokinetics"},{"issue":"4","key":"10.1002\/14651858.CD014570.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1080\/10428194.2016.1218004","article-title":"Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review","volume":"58","author":"Beaupin","year":"2017","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/BLCTT.S245210","article-title":"Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review","volume":"11","author":"Bender","year":"2021","journal-title":"Blood and Lymphatic Cancer-Targets and Therapy"},{"issue":"4","key":"10.1002\/14651858.CD014570.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/leu.2012.325","article-title":"Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia","volume":"27","author":"Bohnstedt","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"10.1002\/14651858.CD014570.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","article-title":"Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations","volume":"32a","author":"Boos","year":"1996","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0050|cit50","unstructured":"Boutron I Page MJ Higgins JP Altman DG Lundh A Hr\u00f3bjartsson A on behalf of the Cochrane Bias Methods Group Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejca.2021.08.025","article-title":"How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review","volume":"157","author":"Brigitha","year":"2021","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.118.1.99","article-title":"Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance","volume":"118","author":"Broome","year":"1963","journal-title":"Journal of Experimental Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014570.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD014570.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1080\/10428194.2017.1397658","article-title":"Severe pegaspargase hypersensitivity reaction rates (grade \u22653) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials","volume":"59","author":"Burke","year":"2018","journal-title":"Leukemia & Lymphoma"},{"issue":"2","key":"10.1002\/14651858.CD014570.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Research synthesis methods"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jclinepi.2016.11.015","article-title":"Additional considerations are required when preparing a protocol for a systematic review with multiple interventions","volume":"83","author":"Chaimani","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0057|cit57","doi-asserted-by":"crossref","unstructured":"Chaimani A Caldwell DM Li T Higgins JP Salanti G Chapter 11: Undertaking network meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch11"},{"issue":"1","key":"10.1002\/14651858.CD014570.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pcl.2014.09.006","article-title":"Treatment of pediatric acute lymphoblastic leukemia","volume":"62","author":"Cooper","year":"2015","journal-title":"The Pediatric clinics of North America"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0059|cit59","unstructured":"Covidence Veritas Health Innovation"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0060|cit60","doi-asserted-by":"crossref","unstructured":"Deeks JJ Higgins JPT Chapter 10: Analysing data and undertaking meta-analyses Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Available from www.training.cochrane.org\/handbook 2019","DOI":"10.1002\/9781119536604"},{"issue":"1","key":"10.1002\/14651858.CD014570.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2141.2011.08588.x","article-title":"l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial","volume":"153","author":"Domenech","year":"2011","journal-title":"British journal of haematology"},{"issue":"8","key":"10.1002\/14651858.CD014570.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood.V99.8.2734","article-title":"Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial","volume":"99","author":"Duval","year":"2002","journal-title":"Blood"},{"issue":"17","key":"10.1002\/14651858.CD014570.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood.2020006583","article-title":"Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia","volume":"137","author":"Gottschalk H\u00f8jfeldt","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD014570.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0169-409X(03)00110-8","article-title":"Pegaspargase: a review of clinical studies","volume":"55","author":"Graham M","year":"2003","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"17","key":"10.1002\/14651858.CD014570.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children's oncology group","volume":"38","author":"Gupta","year":"2020","journal-title":"Journal of clinical oncology"},{"issue":"7650","key":"10.1002\/14651858.CD014570.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt G","year":"2008","journal-title":"British Medical Journal"},{"issue":"10","key":"10.1002\/14651858.CD014570.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/0006-2952(69)90375-X","article-title":"l-asparaginase resistance in human leukemia - asparagine synthetase","volume":"18","author":"Haskell","year":"1969","journal-title":"Biochemical pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD014570.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2141.2009.07923.x","article-title":"A population pharmacokinetic model for pegylated-asparaginase in children","volume":"148","author":"Hempel","year":"2010","journal-title":"British journal of haematology"},{"issue":"2","key":"10.1002\/14651858.CD014570.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/bjh.12865","article-title":"Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia","volume":"166","author":"Henriksen","year":"2014","journal-title":"British journal of haematology"},{"issue":"3","key":"10.1002\/14651858.CD014570.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pbc.25319","article-title":"PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol","volume":"62","author":"Henriksen","year":"2015","journal-title":"Pediatric Blood and Cancer"},{"issue":"12","key":"10.1002\/14651858.CD014570.pub2-BIB0071|cit71","article-title":"Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation","volume":"64","author":"Henriksen","year":"2017","journal-title":"Pediatric Blood and Cancer"},{"issue":"7","key":"10.1002\/14651858.CD014570.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40265-019-01120-1","article-title":"Pegaspargase: A Review in acute lymphoblastic leukaemia","volume":"79","author":"Heo","year":"2019","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0073|cit73","doi-asserted-by":"crossref","unstructured":"Higgins JPT Savovi\u0107 J Page MJ Elbers RG Sterne JAC Chapter 8: Assessing risk of bias in included studies Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). The Cochrane Collaboration, 2019. Available from www.cochrane-handbook.org","DOI":"10.1002\/9781119536604.ch8"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0074|cit74","doi-asserted-by":"crossref","unstructured":"Higgins JPT Eldridge S Chapter 23: Including variants on randomized trials In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0075|cit75","unstructured":"Higgins JPT Savovi\u0107 J Page MJ Elbers RG Sterne JAC Chapter 8: Assessing risk of bias in a randomized trial In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org\/handbook"},{"issue":"16","key":"10.1002\/14651858.CD014570.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute Lymphoblastic Leukemia in Children","volume":"373","author":"Hunger","year":"2015","journal-title":"The New England journal of medicine"},{"issue":"1","key":"10.1002\/14651858.CD014570.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2013-07-453480","article-title":"How I treat ALL in Down's syndrome: pathobiology and management","volume":"123","author":"Izraeli","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1002\/14651858.CD014570.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1002\/sim.6188","article-title":"A design-by-treatment interaction model for network meta-analysis with random inconsistency effects","volume":"33","author":"Jackson","year":"2014","journal-title":"Statistics in medicine"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2019.07.026","article-title":"Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia-a report from the UKALL 2011 trial","volume":"120","author":"Jackson","year":"2019","journal-title":"European journal of cancer"},{"issue":"11","key":"10.1002\/14651858.CD014570.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10552-015-0657-6","article-title":"Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden","volume":"26","author":"Katz","year":"2015","journal-title":"Cancer Causes Control"},{"issue":"7","key":"10.1002\/14651858.CD014570.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2011-09-381731","article-title":"Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia","volume":"119","author":"Kawedia J","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.clml.2014.06.017","article-title":"Asparaginase in Acute Lymphoblastic Leukemia","volume":"14","author":"Kawedia J","year":"2014","journal-title":"Clinical Lymphoma Myeloma & Leukemia"},{"issue":"11","key":"10.1002\/14651858.CD014570.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/pbc.26123","article-title":"Allergic-like reactions to asparaginase: atypical allergies without asparaginase inactivation","volume":"63","author":"Kloos","year":"2016","journal-title":"Pediatric blood & cancer"},{"issue":"12","key":"10.1002\/14651858.CD014570.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1080\/10428194.2019.1613537","article-title":"The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia","volume":"60","author":"Kloos R Q","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1002\/14651858.CD014570.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.19.02292","article-title":"Individualized asparaginase dosing in childhood acute lymphoblastic leukemia","volume":"38","author":"Kloos","year":"2020","journal-title":"Journal of clinical oncology"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0086|cit86","doi-asserted-by":"crossref","unstructured":"Kremer LCM van Dalen EC Cochrane Childhood Cancer Group Module . https:\/\/childhoodcancer.cochrane.org\/sites\/childhoodcancer.cochrane.org\/files\/public\/uploads\/cochrane_childhood_cancer_module_may_2020_0.pdf","DOI":"10.1002\/14651858.CD010885.pub5"},{"issue":"3","key":"10.1002\/14651858.CD014570.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2009.06.027","article-title":"L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL)","volume":"139","author":"Kwon","year":"2009","journal-title":"Journal of controlled release"},{"issue":"3","key":"10.1002\/14651858.CD014570.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jpeds.2012.09.012","article-title":"Validation of Search Filters for Identifying Pediatric Studies in PubMed","volume":"162","author":"Leeflang Mariska M","year":"2013","journal-title":"The Journal of Pediatrics"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0089|cit89","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Chapter 4: Searching for and selecting studies In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD014570.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1158\/1078-0432.CCR-19-1255","article-title":"FDA approval summary: Calaspargase Pegol-mknl for treatment of acute lymphoblastic leukemia in children and young adults","volume":"26","author":"Li","year":"2020","journal-title":"Clinical cancer research"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0091|cit91","unstructured":"Li T Higgins JPT Chapter 5: Collecting data In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org\/handbook"},{"issue":"18","key":"10.1002\/14651858.CD014570.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1200\/JCO.2015.64.5812","article-title":"Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia","volume":"34","author":"Liu","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD014570.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/pbc.22719","article-title":"Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia","volume":"56","author":"Lund","year":"2011","journal-title":"Pediatric blood & cancer"},{"issue":"1","key":"10.1002\/14651858.CD014570.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/bloodadvances.2021005631","article-title":"Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study","volume":"6","author":"Lynggaard","year":"2022","journal-title":"Blood Advances"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0095|cit95","doi-asserted-by":"crossref","unstructured":"McGuinness Luke A Higgins Julian P T Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments Research Synthesis Methods 2020 n\/a n\/a","DOI":"10.1002\/jrsm.1411"},{"issue":"12","key":"10.1002\/14651858.CD014570.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1182\/blood-2007-10-117150","article-title":"Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study","volume":"111","author":"Mody","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD014570.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"e27300","DOI":"10.1002\/pbc.27300","article-title":"Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia","volume":"65","author":"Mogensen","year":"2018","journal-title":"Pediatric blood & cancer"},{"issue":"3","key":"10.1002\/14651858.CD014570.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","article-title":"Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia","volume":"109","author":"Moghrabi","year":"2007","journal-title":"Blood"},{"issue":"17","key":"10.1002\/14651858.CD014570.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood-2015-09-670729","article-title":"Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000","volume":"127","author":"Moricke","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD014570.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"M\u00f6ricke","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD014570.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00280-001-0391-5","article-title":"PEG-asparaginase (Oncaspar) 2500 U\/m(2) BSA in reinduction and relapse treatment in the ALL\/NHL-BFM protocols","volume":"49","author":"M\u00fcller","year":"2002","journal-title":"Cancer chemotherapy and pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD014570.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS medicine"},{"issue":"10","key":"10.1002\/14651858.CD014570.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/MCG.0000000000000827","article-title":"Risk Factors for Asparaginase-associated Pancreatitis: A Systematic Review","volume":"51","author":"Oparaji","year":"2017","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0104|cit104","doi-asserted-by":"crossref","unstructured":"Page MJ Higgins JPT Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org\/handbook.","DOI":"10.1002\/9781119536604"},{"issue":"1","key":"10.1002\/14651858.CD014570.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1002\/cl2.1080","article-title":"CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD014570.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/bjh.12739","article-title":"Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol","volume":"165","author":"Patrick","year":"2014","journal-title":"British journal of haematology"},{"issue":"4","key":"10.1002\/14651858.CD014570.pub2-BIB0107|cit107","first-page":"e500","article-title":"Acute lymphoblastic leukemia in children with Down syndrome: Comparative analysis versus patients without Down syndrome","volume":"116","author":"Pennella","year":"2018","journal-title":"Archivos argentinos de pediatri\u0301a"},{"issue":"28","key":"10.1002\/14651858.CD014570.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"Pession","year":"2005","journal-title":"Journal of clinical oncology"},{"issue":"22","key":"10.1002\/14651858.CD014570.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group","volume":"34","author":"Pieters","year":"2016","journal-title":"Journal of clinical oncology"},{"issue":"16","key":"10.1002\/14651858.CD014570.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"The Lancet. Oncology"},{"issue":"7","key":"10.1002\/14651858.CD014570.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/leu.2009.12","article-title":"Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Munster study group","volume":"23","author":"Prucker","year":"2009","journal-title":"Leukemia"},{"issue":"9617","key":"10.1002\/14651858.CD014570.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD014570.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","article-title":"A 50-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"Pui C","year":"2013","journal-title":"Seminars in hematology"},{"issue":"22","key":"10.1002\/14651858.CD014570.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2018-01-827949","article-title":"Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years","volume":"131","author":"Rank","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD014570.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.19.02208","article-title":"Asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the NOPHO ALL2008 treatment of patients 1-45 years of age","volume":"38","author":"Rank","year":"2020","journal-title":"Journal of clinical oncology"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0116|cit116","unstructured":"Review Manager Web (RevMan Web) [Computer program] The Cochrane Collaboration, available at revman.cochrane.org 2019"},{"issue":"Supplement_1","key":"10.1002\/14651858.CD014570.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2019-123448","article-title":"Incidence of hypersensitivity reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 patients treated in the AIEOP-BFM ALL 2009 Study Protocol","volume":"134","author":"Rizzari","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD014570.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"The Lancet. Oncology"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"444","DOI":"10.12688\/f1000research.10768.1","article-title":"Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy","volume":"6","author":"Schmiegelow","year":"2017","journal-title":"F1000Research"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0120|cit120","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Higgins JPT Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch14"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0121|cit121","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JPT Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org\/handbook.","DOI":"10.1002\/9781119536604.ch15"},{"issue":"1","key":"10.1002\/14651858.CD014570.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pbc.21737","article-title":"Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome","volume":"52","author":"Shah","year":"2009","journal-title":"Pediatric blood & cancer"},{"issue":"5","key":"10.1002\/14651858.CD014570.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD014570.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bjh.12442","article-title":"Predicting relapse risk in childhood acute lymphoblastic leukaemia","volume":"162","author":"Teachey","year":"2013","journal-title":"British journal of haematology"},{"issue":"3","key":"10.1002\/14651858.CD014570.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1002\/14651858.CD014570.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/10428194.2010.537796","article-title":"Asparaginase revisited","volume":"52","author":"den Berg","year":"2011","journal-title":"Leukemia & lymphoma"},{"issue":"3","key":"10.1002\/14651858.CD014570.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"Sluis","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"10.1002\/14651858.CD014570.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"e27083","DOI":"10.1002\/pbc.27083","article-title":"Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group","volume":"65","author":"Sluis","year":"2018","journal-title":"Pediatric blood & cancer"},{"issue":"10","key":"10.1002\/14651858.CD014570.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1080\/1042819021000015853","article-title":"Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma","volume":"43","author":"Vieira Pinheiro","year":"2002","journal-title":"Leukemia & lymphoma"},{"issue":"5","key":"10.1002\/14651858.CD014570.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11899-016-0337-y","article-title":"Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances","volume":"11","author":"Vrooman","year":"2016","journal-title":"Current hematologic malignancy reports"},{"issue":"12","key":"10.1002\/14651858.CD014570.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/bloodadvances.2018016584","article-title":"Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001","volume":"2","author":"Vrooman","year":"2018","journal-title":"Blood advances"},{"key":"10.1002\/14651858.CD014570.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","article-title":"ROBIS: A new tool to assess risk of bias in systematic reviews was developed","volume":"69","author":"Whiting","year":"2016","journal-title":"Journal of clinical epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD014570.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2141.2005.05398.x","article-title":"Acute leukaemia in children with Down syndrome: a population-based Nordic study","volume":"128","author":"Zeller","year":"2005","journal-title":"British journal of haematology"},{"issue":"1","key":"10.1002\/14651858.CD014570.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood.V99.1.245","article-title":"Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome","volume":"99","author":"Zwaan","year":"2002","journal-title":"Blood"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T07:54:07Z","timestamp":1718092447000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014570.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Childhood Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":134,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014570.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]}}}